image
Healthcare - Medical - Devices - NASDAQ - US
$ 1.7
0 %
$ 64.2 M
Market Cap
-3.07
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one APYX stock under the worst case scenario is HIDDEN Compared to the current market price of 1.7 USD, Apyx Medical Corporation is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one APYX stock under the base case scenario is HIDDEN Compared to the current market price of 1.7 USD, Apyx Medical Corporation is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one APYX stock under the best case scenario is HIDDEN Compared to the current market price of 1.7 USD, Apyx Medical Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart APYX

image
$1.8$1.8$1.7$1.7$1.6$1.6$1.5$1.5$1.4$1.4$1.3$1.3$1.2$1.2$1.1$1.1$1.0$1.0$0.9$0.9$0.8$0.815 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
48.1 M REVENUE
-8.11%
-18.8 M OPERATING INCOME
-9.19%
-23.6 M NET INCOME
-24.98%
-18 M OPERATING CASH FLOW
-243.82%
-722 K INVESTING CASH FLOW
-10.72%
6.74 M FINANCING CASH FLOW
-79.03%
9.43 M REVENUE
-33.69%
-3.05 M OPERATING INCOME
-0.10%
-4.17 M NET INCOME
10.45%
-702 K OPERATING CASH FLOW
76.10%
-55 K INVESTING CASH FLOW
77.55%
25 K FINANCING CASH FLOW
-99.63%
Balance Sheet Apyx Medical Corporation
image
Current Assets 56.4 M
Cash & Short-Term Investments 31.7 M
Receivables 15.5 M
Other Current Assets 9.22 M
Non-Current Assets 8.4 M
Long-Term Investments 0
PP&E 6.74 M
Other Non-Current Assets 1.66 M
48.95 %23.87 %14.22 %10.39 %Total Assets$64.8m
Current Liabilities 10.7 M
Accounts Payable 2.62 M
Short-Term Debt 355 K
Other Current Liabilities 7.75 M
Non-Current Liabilities 39.8 M
Long-Term Debt 38.4 M
Other Non-Current Liabilities 1.38 M
5.18 %15.35 %76.05 %Total Liabilities$50.5m
EFFICIENCY
Earnings Waterfall Apyx Medical Corporation
image
Revenue 48.1 M
Cost Of Revenue 18.7 M
Gross Profit 29.4 M
Operating Expenses 48.2 M
Operating Income -18.8 M
Other Expenses 4.71 M
Net Income -23.6 M
50m50m40m40m30m30m20m20m10m10m00(10m)(10m)(20m)(20m)(30m)(30m)48m(19m)29m(48m)(19m)(5m)(24m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
61.04% GROSS MARGIN
61.04%
-39.18% OPERATING MARGIN
-39.18%
-48.78% NET MARGIN
-48.78%
-165.12% ROE
-165.12%
-36.18% ROA
-36.18%
-34.97% ROIC
-34.97%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Apyx Medical Corporation
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -23.6 M
Depreciation & Amortization 599 K
Capital Expenditures -722 K
Stock-Based Compensation 4.01 M
Change in Working Capital -1.24 M
Others 2.14 M
Free Cash Flow -18.8 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Apyx Medical Corporation
image
Wall Street analysts predict an average 1-year price target for APYX of $11.3 , with forecasts ranging from a low of $5 to a high of $17 .
APYX Lowest Price Target Wall Street Target
5 USD 194.12%
APYX Average Price Target Wall Street Target
11.3 USD 566.67%
APYX Highest Price Target Wall Street Target
17 USD 900.00%
Price
Max Price Target
Min Price Target
Average Price Target
181816161414121210108866442200Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Apyx Medical Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
12.8 K USD 1
9-12 MONTHS
7. News
Renuvion® Brings Real Transformations to the Runway at Miami Swim Week Highlighting Real Patient Journeys and Empowering Confidence Through Loose Skin Solutions and Body Contouring CLEARWATER, Fla. , May 30, 2025 /PRNewswire/ -- Apyx® Medical Corporation (NASDAQ: APYX) ("Apyx Medical" or the "Company"), the manufacturer of the proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, is once again taking center stage—this time at Miami Swim Week. prnewswire.com - 2 weeks ago
Apyx Medical Corporation Receives FDA Clearance for the AYON Body Contouring System™ The AYON Body Contouring System is the first FDA cleared all-in-one platform for the aesthetic surgical suite Plan to initiate the commercial launch of the AYON Body Contouring System to key opinion leader surgeons in critical geographies during the second half of 2025 CLEARWATER, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, is pleased to announce it has received 510(k) clearance from the U.S. Food and Drug Administration (the “FDA”) for the AYON Body Contouring System™ (“AYON”). globenewswire.com - 1 month ago
Apyx Medical Corporation (APYX) Q1 2025 Earnings Call Transcript Apyx Medical Corporation (NASDAQ:APYX ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Jeremy Feffer – LifeSci Advisors Charlie Goodwin – Chief Executive Officer Matt Hill – Chief Financial Officer Conference Call Participants Matt Hewitt – Craig-Hallum Capital Group Sam Eiber – BTIG Operator Ladies and gentlemen, good morning, and welcome to the Apyx Medical First Quarter 2025 Earnings Conference Call. At this time all participants are in a listen-only mode. seekingalpha.com - 1 month ago
Renuvion Introduces Television Star Dolores Catania as Chief of Confidence Beloved Personality of "The Real Housewives of New Jersey" Provides a Real Take on the Problem of Loose Skin and the Power of Body Contouring Technology CLEARWATER, Fla. , May 1, 2025 /PRNewswire/ -- Apyx® Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion® today announces Dolores Catania as the Chief of Confidence for the brand's Renew You consumer marketing campaign which exemplifies the brand's ability to reshape bodies and lives. prnewswire.com - 1 month ago
Apyx Medical Corporation Announces Two Peer-Reviewed Publications on the Use of Renuvion in Abdominal Body Contouring Procedures Two studies report favorable clinical outcomes and safety data for Renuvion ® when used during procedures that include lipoabdominoplasty for the treatment of loose and lax skin Rapid weight loss due to GLP-1 drugs expected to drive growth in patients seeking treatment for loose and lax skin CLEARWATER, Fla., April 29, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (“Apyx Medical” or the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform marketed and sold as Renuvion®, today announced the publication of two peer-reviewed clinical studies evaluating the use of Renuvion during body contouring procedures that also included lipoabdominoplasty1. globenewswire.com - 1 month ago
Apyx Medical Corporation to Release First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025 CLEARWATER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the first quarter of fiscal year 2025 will be released before markets open on Thursday, May 8th. globenewswire.com - 1 month ago
Renuvion wins 2025 NewBeauty Award for "Best Minimally Invasive Skin Tightener" Renuvion is the first and only body contouring technology that empowers consumers to feel and look their best, from the inside out by treating loose skin CLEARWATER, Fla. , March 25, 2025 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ: APYX) ("Apyx Medical" or the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, announced today that Renuvion has been named this year's NewBeauty Award winner in the "Best Minimally Invasive Skin Tightener"1 category. prnewswire.com - 2 months ago
Apyx Medical Corporation (APYX) Q4 2024 Earnings Call Transcript Apyx Medical Corporation (NASDAQ:APYX ) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Jeremy Feffer - MD, LifeSci Advisors Charlie Goodwin - CEO Matt Hill - CFO Conference Call Participants Matthew O'Brien - Piper Sandler Matt Hewitt - Craig-Hallum Capital Group Sam Eiber - BTIG Operator Greetings. Welcome to the Apyx Medical Fourth Quarter and Full Year 2024 Conference Call. seekingalpha.com - 3 months ago
Apyx Medical (APYX) Reports Q4 Loss, Tops Revenue Estimates Apyx Medical (APYX) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.19 per share a year ago. zacks.com - 3 months ago
Apyx Medical Corporation Submits 510(k) Premarket Notification to the U.S. Food and Drug Administration for the AYON Body Contouring System™ Focusing on advancing body contouring by providing the first all-in-one platform for the surgical suite Focusing on advancing body contouring by providing the first all-in-one platform for the surgical suite globenewswire.com - 5 months ago
Apyx Medical Corporation to Attend 15th Annual Craig-Hallum Alpha Select Conference CLEARWATER, Fla., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that Charles Goodwin, President and CEO and Matt Hill, CFO will be attending the following upcoming conference: globenewswire.com - 7 months ago
Apyx Medical Corporation (APYX) Q3 2024 Earnings Call Transcript Apyx Medical Corporation (NASDAQ:APYX ) Q3 2024 Earnings Call Transcript November 8, 2024 8:00 AM ET Company Participants Jeremy Feffer - MD, LifeSci Advisors Stavros Vizirgianakis - Executive Chairman Charlie Goodwin - CEO Matt Hill - CFO Conference Call Participants Matthew O'Brien - Piper Sandler Matt Hewitt - Craig-Hallum Capital Group Sam Eiber - BTIG Ben Haynor - Lake Street Capital Markets Operator Ladies and gentlemen, good morning, and welcome to the Apyx Medical Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 7 months ago
8. Profile Summary

Apyx Medical Corporation APYX

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 64.2 M
Dividend Yield 0.00%
Description Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Contact 5115 Ulmerton Road, Clearwater, FL, 33760 https://www.apyxmedical.com
IPO Date Jan. 2, 2019
Employees 220
Officers Mr. Charles D. Goodwin II President, Chief Executive Officer & Director Mr. Matthew C. Hill CPA Chief Financial Officer, Treasurer & Secretary Mr. Stavros George Vizirgianakis B.Com. Executive Chairman Mr. Shawn D. Roman Chief Operating Officer Ms. Dolores Catania Chief of Confidence Mr. Moshe Citronowicz Senior Vice President